WO1985005036A1 - Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch - Google Patents
Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch Download PDFInfo
- Publication number
- WO1985005036A1 WO1985005036A1 PCT/US1985/000695 US8500695W WO8505036A1 WO 1985005036 A1 WO1985005036 A1 WO 1985005036A1 US 8500695 W US8500695 W US 8500695W WO 8505036 A1 WO8505036 A1 WO 8505036A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- layer
- skin
- insulin
- gel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Definitions
- Exogenous insulin is the mainstay of therapy for human diabetics.
- a major disadvantage is the necessity to administer the drug parenterally, e.g., with a needle and syringe.
- the need for at least daily injections of insulin is an important factor in patient compliance and comfort.
- Penetrant enhancers other than DMSO are known. [Dugard,
- the present invention overcomes these difficulties and provides a method for treating diabetes involving topical application of a composition to the surface of the skin or a diabetic subject.
- a composition which when applied to the surface of the skin of a diabetic subject or patient is useful in the treatment of diabetes, comprises a first layer in contact with the skin surface and a second layer covering the first layer.
- the first layer includes an effective diabetes-treating amount of insulin, an effective enhancing amount of a penetrant enhancer such as dimethyl sulfoxide or n-decyl-methyl sulf- oxide and a suitable carrier.
- the second layer comprises a suitable adherent, nonporous patch material such as poly ⁇ ethylene.
- the first layer is in the form of a gel and includes a suitable gel material such as hydroxymethyl cellulose, hydroxypropylmethyl cellulose or hydroxypropyl cellulose.
- compositions which when applied to the surface of a diabetic patient's or subject's skin are useful in treating diabetes.
- such a composition includes a first layer in contact with the skin surface and a second layer covering the first layer.
- the first layer includes an effective diabetes-treating amount of insulin, an effective enhancing amount of a penetrant enhancer and a suitable carrier.
- the second layer comprises a suitable adherent, nonporous patch material.
- the first layer may be formulated directly on the surface of the skin, it is generally preferable to first formulate the ingredients and then apply the formulated ingredients to the skin surface to form the layer.
- Effective diabetes-treating amounts of insulin may vary from the amounts normally required for subcutaneous or intravenous therapy. However, in the practices of the present invention it is contemplated that the amounts will be similar to those presently employed in the other treat- ment modes since one unit of protamine zinc insulin admin ⁇ istered subcutaneously is an appropriate dose for main ⁇ tenance of relative normoglycemia in diabetic rodents [Andersson, A., Diabetologia __ : 269 (1983)].
- the form of insulin may also vary and includes regular insulin, NPH, Lente and protamine zinc insulin. It is contemplated that insoluble repository forms of insulin may have longer dura ⁇ tions of action than regular insulin.
- the penetrant enhancer may be any of a number of agents known to enhance the penetration and increase the absorption of drugs across the skin. Examples include dimethyl sulfoxide, dimethyl acetamide, dimethylformamide and n-decyl-methyl sulfoxide. Additional such agents include propylene gly- col, glycerin, lanolins, alcohols, anionic emulsifiers (e.g. sodium lauryl sulfate) and surfactants (nonionic emulsifiers such as polyoxyethylene fatty alcohol ethers and esters; polyoxyethylene fatty acid esters, e.g.
- poly ⁇ oxyethylene stearate polyoxyethylene sorbitan fatty acid esters and sorbitan fatty acid esters, e.g. sorbitan mon- ostearate; polyoxyethylene glycol fatty acid esters; polyol fatty acid esters, e.g. glyceryl monostearate; and ethoxy- lated lanolin derivatives.
- DMSO dimethylacetamide, dimethylformamide and most particularly N-decyl-methyl sulfoxide
- NDMS N-decyl-methyl sulfoxide
- N-decyl-methyl sulfoxide is at least 15 times more effective than DMSO in skin penetrance enhancement [McCullough, J.L. et al., J. Invest. Dermatol. 6 ⁇ :103 (1976)], and in a less than 1% solution, applied topically, in amounts less than 1.3 ml per day, is safe and without side effects [Physicians Desk Reference, Medical Economics Company, Oradell, New Jersey- (1983)]. Substitution of NDMS for DMSO or lowering the amount of enhancing agent used is particularly desirable since DMSO has several undesirable, dose-related side ef ⁇ fects. [Harter, J., Annals of the New York Academy of Sciences, Vol. 411, Ed., J.C.
- DMSO in 50% aqueous solution is FDA approved for instillation in the bladder to treat interstitial cystitis [Stewart, B. et al., J. Urology Ll :36 (1976)]. It i expected that biological effects of DMSO in penetr-anc-, enhancement of insulin transport across the skin, even at concentrations as low as 1-5% will be effective since Whitworth and Stevenson.[J. Pharmaceut. Sci. 6 :48 (1971)]
- the amount of penetrant enhancer present in the first layer may vary over a wide range, depending upon the specific enhancer beinj used. In general, the amount will not exceed about 50% by volume of the first layer.
- the first layer also includes a suitable carrier.
- a suitable carrier is water, e.g., deionized dis ⁇ tilled water.
- Other carriers include alcohols such as methanol or ethanol or aqueous mixtures thereof.
- the carrier may be formulated in an emulsion or cream base.
- Hydrophilic Ointment USP a widely available oil-in-water emulsion.
- Hydrophilic Petrolatum USP a water- and-oil emulsion (Table 2).
- the first layer may also include additional materials such as emulsifying agents, suspending agents, preservatives and the like.
- the first layer is in the form of a gel.
- Suitable gel materials include hydroxymethyl cel ⁇ lulose, hydroxypropylmethyl cellulose or hydroxypropyl cellulose.
- the use of a gel permit easier application of the insulin and penetrant enhancer to the diabetic subject's skin. In addition, it permits better control over dosage amounts. Finally, it maintains the components of the firs- layer in contact with a defined area of the subject's ski; prior to application of the adherent, nonporous patch.
- the amount of gel material employed may vary widely depend ⁇ ing upon the identity of the gel material and the identity and amount of penetrant enhancer and carrier. In general, the amount of gel material will not exceed about 50% by volume of the first layer. In one preferred embodiment cf the invention the gel material and penetrant enhancer eacr comprise about 33% by volume of the first layer.
- the adherent, nonporous patch material may be any of th ⁇ various such materials known to be useful as a patch.
- a patch material useful in the practices of this invention is polyethylene. .
- This invention provides a method of treating diabetes which comprises applying to the surface of a diabetic subject' skin a composition of the type described herein for suitable period of time, such as 1-12 hours, to perm insulin present in the composition to penetrate across ____: skin, enter the bloodstream and effect blood sugar levels,
- Bovine-porcine regular insulin (Eli Lilly and Company, Indianapolis, Indiana) was topically applied to the skin of streptozotocin-diabetic male BO.BR mice, beneath a poly ⁇ ethylene patch (SteridrapeTM - 3M Company, Minneapolis, Minnesota), which was applied to the torso. Drug-skin contact occurred over approximately 1-2 cm ⁇ of body surface. Body hair was clipped 24-72 hours prior to each experiment. Mice were awake with free access to food and water. Animals were judged diabetic if they had more than three blood glucose values >40Q mg/dl over at least 10 days. Blood glucose was measured by the glucose oxidase technique on tail vein blood (Ames dextrometer) [Jarett, R. et al., Diabetes 3,9:7234 (1970)].
- dimethyl sulfoxide 33% or 50% (DMSO-Sigma) was mixedwith insulin.
- DMSO added to 100 units of regular insulin resulted in reductions of blood glucose in 8 of 13 mice.
- DMSO alone had no effect on blood sugar.
- NDMS n-decyl-methyl sulfoxide
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60560884A | 1984-04-30 | 1984-04-30 | |
US605,608 | 1984-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1985005036A1 true WO1985005036A1 (en) | 1985-11-21 |
Family
ID=24424421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1985/000695 WO1985005036A1 (en) | 1984-04-30 | 1985-04-17 | Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0178321A1 (de) |
AU (1) | AU4292585A (de) |
WO (1) | WO1985005036A1 (de) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011705A1 (en) * | 1994-10-13 | 1996-04-25 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
US5820876A (en) * | 1986-08-28 | 1998-10-13 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system |
WO1998053847A1 (en) * | 1997-05-29 | 1998-12-03 | Ben Gurion University Of The Negev Research And Development Authority | Transdermal delivery system |
US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
EP1017414A1 (de) * | 1997-06-23 | 2000-07-12 | The Research Foundation Of State University Of New York | Therapieverfahren zur behandlung von diabetes mellitus |
US6110488A (en) * | 1986-08-28 | 2000-08-29 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
US6117448A (en) * | 1986-08-28 | 2000-09-12 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
US6126963A (en) * | 1986-08-28 | 2000-10-03 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
US6139868A (en) * | 1986-08-28 | 2000-10-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
USRE37934E1 (en) | 1986-08-28 | 2002-12-10 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system |
US6667052B2 (en) * | 1997-05-29 | 2003-12-23 | Ben Gurion University Of The Negev Research And Development Authority | Transdermal delivery system |
WO2005112889A2 (en) * | 2004-05-20 | 2005-12-01 | Recordati Ireland Limited | Transmucosal delivery formulations |
US7402571B2 (en) | 2000-07-31 | 2008-07-22 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US7638484B2 (en) | 2003-08-07 | 2009-12-29 | Healor Ltd. | Methods for accelerating wound healing by administration of adipokines |
US8093211B2 (en) | 2000-07-31 | 2012-01-10 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US8349793B2 (en) | 2010-01-11 | 2013-01-08 | Heal0r, Ltd. | Method for treatment of inflammatory disease and disorder |
US20140205559A1 (en) * | 2011-05-11 | 2014-07-24 | Alc Therapeutics, Llc | Antifungal compositions for the treatment of skin and nails |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE50502T1 (de) * | 1984-06-09 | 1990-03-15 | Hoechst Ag | Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung. |
AUPN089295A0 (en) * | 1995-02-02 | 1995-03-02 | International Diabetes Institute | Treatment of diabetic neuropathy |
-
1985
- 1985-04-17 EP EP19850902306 patent/EP0178321A1/de not_active Withdrawn
- 1985-04-17 WO PCT/US1985/000695 patent/WO1985005036A1/en unknown
- 1985-04-17 AU AU42925/85A patent/AU4292585A/en not_active Abandoned
Non-Patent Citations (5)
Title |
---|
Published, 05 September 1967 CHEN et al. * |
Published, 08 September 1970 MacMILLAN et al * |
Published, 10 April 1982, NIHO Electric Ind. KK * |
Published, 11 March 1975, LOWEY et al. * |
Published, 20 April 1976, SMITH * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117448A (en) * | 1986-08-28 | 2000-09-12 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
USRE37934E1 (en) | 1986-08-28 | 2002-12-10 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system |
US5820876A (en) * | 1986-08-28 | 1998-10-13 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system |
US6264977B1 (en) | 1986-08-28 | 2001-07-24 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
US6224900B1 (en) | 1986-08-28 | 2001-05-01 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Sealing bag for a transdermal therapeutic system |
US6139868A (en) * | 1986-08-28 | 2000-10-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
US6126963A (en) * | 1986-08-28 | 2000-10-03 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
US6110488A (en) * | 1986-08-28 | 2000-08-29 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
WO1996011705A1 (en) * | 1994-10-13 | 1996-04-25 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
AU716868B2 (en) * | 1994-10-13 | 2000-03-09 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
US6667052B2 (en) * | 1997-05-29 | 2003-12-23 | Ben Gurion University Of The Negev Research And Development Authority | Transdermal delivery system |
WO1998053847A1 (en) * | 1997-05-29 | 1998-12-03 | Ben Gurion University Of The Negev Research And Development Authority | Transdermal delivery system |
US6274166B1 (en) * | 1997-05-29 | 2001-08-14 | Ben Gurion University Of The Negev Research And Development Authority | Transdermal delivery system |
EP1017414A1 (de) * | 1997-06-23 | 2000-07-12 | The Research Foundation Of State University Of New York | Therapieverfahren zur behandlung von diabetes mellitus |
EP1017414A4 (de) * | 1997-06-23 | 2004-10-06 | Res Foundation Ofstate Univers | Therapieverfahren zur behandlung von diabetes mellitus |
US7402571B2 (en) | 2000-07-31 | 2008-07-22 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US8093211B2 (en) | 2000-07-31 | 2012-01-10 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US7638484B2 (en) | 2003-08-07 | 2009-12-29 | Healor Ltd. | Methods for accelerating wound healing by administration of adipokines |
WO2005112889A2 (en) * | 2004-05-20 | 2005-12-01 | Recordati Ireland Limited | Transmucosal delivery formulations |
WO2005112889A3 (en) * | 2004-05-20 | 2006-08-03 | Recordati Ireland Ltd | Transmucosal delivery formulations |
US8349793B2 (en) | 2010-01-11 | 2013-01-08 | Heal0r, Ltd. | Method for treatment of inflammatory disease and disorder |
US20140205559A1 (en) * | 2011-05-11 | 2014-07-24 | Alc Therapeutics, Llc | Antifungal compositions for the treatment of skin and nails |
US9408867B2 (en) * | 2011-05-11 | 2016-08-09 | Veloce Biopharma, Llc | Antifungal compositions for the treatment of skin and nails |
Also Published As
Publication number | Publication date |
---|---|
AU4292585A (en) | 1985-11-28 |
EP0178321A1 (de) | 1986-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1985005036A1 (en) | Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch | |
Gajraj et al. | Eutectic mixture of local anesthetics (EMLA®) cream | |
US6274166B1 (en) | Transdermal delivery system | |
KR101706549B1 (ko) | 히알루로니다제를 포함하는 국소지방 제거용 주사제 조성물 | |
US4725609A (en) | Method of promoting healing | |
US5145679A (en) | Topical emollient for prevention and treatment of circulatory induced lesions | |
IE59827B1 (en) | Antibacterial cream | |
JPS61186317A (ja) | 経皮吸収製剤組成物 | |
US4782049A (en) | Tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis | |
EP0462075B1 (de) | Verwendung von Uridin zur pharmakologischen Behandlung der peripheren Komplikationen bei Diabetes | |
KR102165993B1 (ko) | 국소 지방 제거용 주사제 조성물 | |
JPH01287041A (ja) | 徐放性製剤 | |
Pătraşcu et al. | Ulcerated necrobiosis lipoidica to a teenager with diabetes mellitus and obesity | |
JPH01503146A (ja) | 身体組織の治療方法および身体組織への医薬の投与方法 | |
DE68911132T2 (de) | Hematopoietische kolonien stimulierende faktoren zur verbesserung des lipoprotein/cholesterin-profils. | |
US5200396A (en) | Method of treating neurodegenerative disorders using epidermal growth factor | |
US5006510A (en) | Method for relieving chronic pain with a somatostatin analog composition | |
EP2076243B1 (de) | Flüssigformulierung von g-csf | |
ZA200500710B (en) | A platform for transdermal formulations (PTF). | |
US6667052B2 (en) | Transdermal delivery system | |
KR102517928B1 (ko) | 히알루로니다제 및 콜린알포세레이트를 포함하는 국소 지방 제거용 주사제 조성물 | |
HU223205B1 (hu) | Helyileg alkalmazható készítmény peptidszerű gyógyhatású vegyületek élő szervezetbe vitelére | |
WO1993010795A1 (en) | Topical emollient for prevention and treatment of circulatory induced lesions | |
JPS60174726A (ja) | 注射用医薬組成物 | |
CN115364097B (zh) | 一种含杂原子环丁烷取代基的吡啶酮衍生物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AU DK JP |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |